InsiderPulse
Dashboard

BBIO

BridgeBio Pharma, Inc.

Health CareRussell 2000

BridgeBio Pharma, Inc. insider trading

BridgeBio Pharma, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Palo Alto, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent BBIO insider transactions

5 insiders traded BBIO on the open market between Jun 05, 2026 and Sep 17, 2026 — 24 sales worth $30.7M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$30.7M

24 of 24 on a 10b5-1 plan

Net
−$30.7M
Insiders
5

Open-market purchases (code P) and sales (code S) from BridgeBio Pharma, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every BBIO Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

BBIO insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 17 insiders traded BBIO on the open market: 0 purchases and 210 sales worth $992.7M, 190 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 171 sales ($130.4M), by 11 insiders.

QuarterBoughtSold
Q2 2026—−$25.9M45 sales · all on a plan
Q1 2026—−$27.8M49 sales · all on a plan
Q4 2025—−$45.1M47 sales · 41 on a plan
Q3 2025—−$31.5M30 sales · 27 on a plan
Q2 2025—−$375.2M16 sales · 8 on a plan
Q1 2025—−$336.3M15 sales · 13 on a plan
Q4 2024—−$707.1K3 sales · all on a plan
Q3 2024—−$150.1M5 sales · 4 on a plan
Largest sale
−$205.2M of BBIO by Kravis Henry R (10% Owner) on May 12, 2025.

Open-market transactions through Jun 30, 2026most recent first

  • Cook Jennifer E.10b5-1

    Director

    −$5.9M

    Jun 15, 2026

    88,737 sh · $66.62

  • Cook Jennifer E.10b5-1

    Director

    −$100.9K

    Jun 15, 2026

    1,503 sh · $67.14

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$572.7K

    Jun 05, 2026

    8,437 sh · $67.88

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$480.3K

    Jun 05, 2026

    7,148 sh · $67.20

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$480.3K

    Jun 05, 2026

    7,147 sh · $67.20

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$304.5K

    Jun 05, 2026

    4,416 sh · $68.96

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$304.5K

    Jun 05, 2026

    4,415 sh · $68.96

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$1.1M

    Jun 04, 2026

    15,921 sh · $67.74

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$144.6K

    Jun 04, 2026

    2,200 sh · $65.72

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$95.3K

    Jun 04, 2026

    1,429 sh · $66.72

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$30.7K

    Jun 04, 2026

    450 sh · $68.27

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$792.9K

    May 21, 2026

    11,250 sh · $70.48

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$459.3K

    May 21, 2026

    6,725 sh · $68.30

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$351.1K

    May 21, 2026

    5,072 sh · $69.22

  • Kumar Neil10b5-1

    Chief Executive Officer · Director

    −$152.4K

    May 21, 2026

    2,256 sh · $67.57

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

BridgeBio Pharma, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Palo Alto, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001743881
Previously filed as
BridgeBio Pharma LLC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought BBIO

What the stock actually did in the 90 days following each open-market purchase

Don't check BBIO — let it ping you

Get told the moment an insider moves on BBIO

Pro watches BridgeBio Pharma, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add BBIO to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track BBIO on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read BBIO insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

CYTKDAWNDYNIMVTINSMIOVAITCIKYMRLEGNMDGLMRUSNUVL
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are BBIO insiders buying or selling?
Between Jun 05, 2026 and Sep 17, 2026, 5 BridgeBio Pharma, Inc. insiders made no open-market purchases and 24 sales worth $30.7M, a net sale of $30.7M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much BBIO stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 17 BridgeBio Pharma, Inc. insiders made no open-market purchases and 210 sales worth $992.7M. 190 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 171 sales ($130.4M). The largest sale was Kravis Henry R selling $205.2M on May 12, 2025.
What was the largest recent BBIO insider trade?
Cook Jennifer E. (Director) sold $10.1M of BBIO stock on Jul 09, 2026 at about $90.00 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy BBIO shares?
No open-market purchase by a BridgeBio Pharma, Inc. insider appears in the filings from Jun 05, 2026 to Sep 17, 2026 — every recorded open-market transaction in that period was a sale.
Where does BBIO insider trading data come from?
From the Form 4 filings BridgeBio Pharma, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.